Roche to pay Blueprint up to $1.7 billion in cancer drug deal

This post was originally published on this site

ZURICH (Reuters) – Swiss drugmaker Roche (ROG.S) on Tuesday struck a deal worth up to $1.7 billion with Blueprint Medicines (BPMC.O) to develop and commercialise a new treatment for people with so-called RET-altered cancers whose mutations can …

Click here to read full article